Husain MI

Psilocybin.

Rosenblat JD, Husain MI

Real-World Therapeutic Use of Ketamine in Clinical and Non-Clinical Settings: A Cross-Sectional Survey.

Syed OA, Petranker R, Nestor SM +6

Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review.

Orsini DK, Wong S, Di Luch S +15

Clinical Predictors of Antidepressant Effects of Ketamine and Esketamine in Treatment-Resistant Unipolar and Bipolar Depression: A Systematic Review.

Syed OA, Sobolenko V, Nestor SM +4

Psychedelic Therapies for Comorbid Major Depressive Disorder and Chronic Pain: A Review of Putative Mechanisms of Action.

Kazdan J, Ladha KS, Husain MI

The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis.

Goodwin GM, Aaronson ST, Alvarez O +23

Magnitude of response in treatment and control groups within psychedelic trials for psychiatric disorders: A meta-analysis.

Meshkat S, Lin Q, Sousa-Ho R +15

Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis.

Syed OA, Tsang B, Nestor SM +4

ArticleMDMA

Adverse events associated with classic psychedelics and MDMA: a real-world population-based study using the WHO pharmacovigilance database (VigiBase).

Syed OA, Nestor SM, Husain MI +3

Psilocybin-assisted psychotherapy for treatment-resistant obsessive-compulsive disorder: protocol for an open-label pilot study.

Ledwos N, Baer J, Husain MI +11

Psilocybin in late-life mental health: Addressing depression, loneliness, and existential anxiety.

Konstantinou GN, Rosenblat J, Hales S +2

ArticleMDMA

Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.

Højlund M, Kafali HY, Kırmızı B +33

Adverse event reporting and management in psilocybin therapy clinical trials: A systematic review to guide clinical and research protocol development.

Bukovsky D, Amaev A, Song J +8

Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review.

Wong S, Jones BDM, Thiyagarajah MT +10

Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].

Goodwin GM, Aaronson ST, Alvarez O +28

Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis.

Wong S, Meckling G, Fabiano N +11

Mapping psilocybin therapy: A systematic review of therapeutic frameworks, adaptations, and standardization across contemporary clinical trials.

Kittur ME, Burgos M LA, Jones BDM +4

Non-hallucinogenic psychedelics for mood and anxiety disorders: A systematic review.

Chen MJQ, Chen-Li D, Chisamore N +7

Pharmacokinetics of Psilocybin: A Systematic Review.

Meshkat S, Al-Shamali H, Perivolaris A +13

Mortality risk among people receiving acute hospital care for hallucinogen use compared with the general population.

Myran DT, Xiao J, Fabiano N +8

Psychedelics and Suicide-Related Outcomes: A Systematic Review.

Meshkat S, Malik T, Zeifman R +13

Emergency Department Visits Involving Hallucinogen Use and Risk of Schizophrenia Spectrum Disorder.

Myran DT, Pugliese M, Xiao J +9

Preferences, Perceptions, and Environmental Considerations of Natural and Synthetic Psychedelic Substances: Findings from the Global Psychedelic Survey.

Syed OA, Petranker R, Fewster EC +5

The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.

Goodwin GM, Aaronson ST, Alvarez O +28

Prospective Preference Assessment for the Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN (PEACE-PAIN) Trial.

Lee J, Philip K, Wijeysundera DN +7

Global Trends in Psychedelic Microdosing: Demographics, Substance Testing Behavior, and Patterns of Use.

Syed OA, Petranker R, Fewster EC +5

Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression.

Poulin JM, Bigford GE, Lanctôt KL +13

Disability rights and experiential use of psychedelics in clinical research and practice.

Golafshani M, Buchman DZ, Husain MI

Neural effects of psychedelics: Complexity the key word.

Jones BDM, Husain MI

ArticleMDMA

Aggressive behaviours associated with MDMA and psychedelics: a narrative review.

Sayrafizadeh N, Ledwos N, Husain MI +1

Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.

Haikazian S, Chen-Li DCJ, Johnson DE +6

Ketamine for bipolar depression: an updated systematic review.

Fancy F, Haikazian S, Johnson DE +5

Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders.

Wong S, Yu AY, Fabiano N +7

Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial.

Husain MI, Blumberger DM, Castle DJ +8

Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects.

Rosenblat JD, Leon-Carlyle M, Ali S +2

Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?

Husain MI, Ledwos N, Fellows E +5

Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder.

Ledwos N, Rodas JD, Husain MI +2

A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap.

Ledwos N, Rosenblat JD, Blumberger DM +4

A century of research on psychedelics: A scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs.

Solmi M, Chen C, Daure C +14

The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.

Rosenblat JD, Husain MI, Lee Y +18

Can the revival of serotonergic psychedelic drugs as treatments for mental disorders help to characterize their risks and benefits?

Husain MI, Umer M, Mulsant BH